Amorfix recruits ALS leader, Joseph Beckman, Ph.D. to join Scientific Advisory Board



    TSX Venture: AMF

    TORONTO, June 7 /CNW/ - Amorfix Life Sciences (TSX-V:AMF), a company
focused on diagnostics and treatments for brain wasting diseases, announced
today that Joseph Beckman, Ph.D., will join the Company's Scientific Advisory
Board. Dr. Beckman is an expert in Amyotrophic Lateral Sclerosis (ALS) disease
and the role of superoxide dismutase-1 (SOD1) in this disease. Amorfix's
therapeutic program for ALS targets SOD1.
    "The addition of Dr. Beckman to our advisory board demonstrates the
ability of Amorfix and our therapeutic technology to attract leaders from the
international scientific community. His research expertise in ALS and SOD1 is
an excellent fit for our work in this area under the leadership of our Founder
and Chief Scientific Officer, Dr. Neil Cashman," said Dr. George Adams, Chief
Executive Officer of Amorfix. "We continue to advance our ALS program and
recently published an article in Nature Medicine related to our therapeutic
approach toward ALS and the role of SOD1 in the disease."
    "The Amorfix team are working on a promising approach to treat ALS. I
embraced the opportunity to advise and support their attempts to find an
effective treatment for this devastating disease," said Dr. Beckman.
    Dr. Beckman holds the Ava Helen Pauling Chair in the Linus Pauling
Institute, is a Professor in the Department of Biochemistry and Biophysics and
serves as the Director, Environmental Health Sciences Center at Oregon State
University. He is an active contributor to a number of professional
associations and has served as a regular reviewer for the National Institutes
of Health and on a number of editorial boards of scientific journals.

    About ALS and Amorfix's Therapeutic Program

    ALS is a neurodegenerative disease in which aggregated misfolded proteins
are thought to be a major pathway in the progressive killing of motor neuron
cells. These neurons control the movement of all voluntary muscles. As more
and more motor neurons die, the patient's muscles progressively atrophy and
they become paralyzed. The protein that has been shown to misfold and
aggregate in familiar ALS patients is called superoxide dismutase-1 (SOD1). In
2006, Amorfix acquired certain SOD1 technologies and exclusively licensed
additional SOD1 technologies from Dr. Cashman and his co-inventors for
diagnostic and therapeutic applications for ALS disease. Amorfix has
established a research plan to enable proof-of-concept studies to validate the
Company's therapeutic approach to the treatment of ALS. In August 2006, the
Company signed a research and investment agreement with Biogen Idec which
included an option for Biogen to license the exclusive worldwide rights to
certain Amorfix technology to develop and commercialize therapeutic products
directed against ALS.

    About Amorfix

    Amorfix is an emerging theranostics company focused on the diagnosis and
treatment of brain-wasting diseases, where aggregated misfolded proteins
(AMPs) are prevalent. These include "prions", the infectious agents of the
Transmissible Spongiform Encephalopathies (TSE), such as BSE and variant CJD,
as well as degenerative diseases such as Alzheimer's Disease, ALS and
Parkinson's Disease. Amorfix is focused on discovering and commercializing
technologies to become the world leader on AMP diseases. The company will use
this knowledge to develop diagnostic kits, treatments and vaccines for AMP
diseases.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this release. This
    information release may contain certain forward-looking information. Such
    information involves known and unknown risks, uncertainties and other
    factors that may cause actual results, performance or achievements to be
    materially different from those implied by statements herein, and
    therefore these statements should not be read as guarantees of future
    performance or results. All forward-looking statements are based on the
    Company's current beliefs as well as assumptions made by and information
    currently available to it as well as other factors. Readers are cautioned
    not to place undue reliance on these forward-looking statements, which
    speak only as of the date of this press release. Due to risks and
    uncertainties, including the risks and uncertainties identified by the
    Company in its public securities filings, actual events may differ
    materially from current expectations. The Company disclaims any intention
    or obligation to update or revise any forward-looking statements, whether
    as a result of new information, future events or otherwise.

    %SEDAR: 00022789E




For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 482-3813, Fax: (416) 482-3811,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 482-3814, Fax: (416) 482-3811,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890